Cadent Therapeutics is creating breakthrough therapies for neurological and psychiatric conditions. The company is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders. In December 2020 Novartis acquired Cadent for up to $770 million.
| Headquarters | Cambridge, MA |
| Website | www.cadenttx.com |
| Pipeline | Phase 2 |
| Partners | Novartis |
| @CadentTx |